Adamo Robot achieves CE Mark as a Class IIa Medical Device.
We are proud to announce that Adamo Robot SL, part of the Inspiralia Group, has officially obtained the CE mark as a Class IIa Medical Device under the European Medical Device Regulation (MDR 2017/745). This certification marks a historic milestone for our organisation, validating years of dedication, innovation, and teamwork.
A long and demanding journey
Obtaining the CE mark under the latest European MDR is not an easy task. It requires not only cutting-edge technology but also a robust quality management system, detailed technical documentation, and rigorous testing. The process is well-known in the health sector for being demanding, lengthy, and costly. For Adamo Robot, this journey began back in 2022, with a clear vision: to create a collaborative robot that could make a real difference in the treatment of musculoskeletal disorders.
Since then, our team has poured countless hours into research, design, validation, and clinical testing. Each step brought us closer to the goal of ensuring that Adamo Robot could be used safely and effectively by healthcare professionals across Europe. This CE certification confirms that our system meets the highest regulatory standards and can now be marketed as a Class IIa Medical Device throughout the EU.
Why this certification matters
The CE mark is more than a regulatory stamp; it is a guarantee of trust. For patients, this means they can benefit from a device that has been thoroughly assessed and validated for both safety and effectiveness. For healthcare professionals, it provides reassurance that the tool they are using meets strict European standards. For our partners and collaborators, this marks a significant milestone, demonstrating that Adamo Robot has reached a new level of maturity and reliability.
The device itself is designed as a physiotherapy collaborative robot that assists in treating musculoskeletal disorders. It does not replace healthcare professionals but supports them in their daily work, improving efficiency, accuracy, and patient outcomes. Beyond physical treatment, Adamo Robot also generates valuable clinical data that can aid in early diagnosis and long-term monitoring of conditions — bridging technology with preventive healthcare.
What this means for the future
For Adamo Robot, the CE certification opens the door to broader adoption across European healthcare systems. Hospitals, clinics, and rehabilitation centres can now integrate our technology into their practices with confidence, knowing it meets all regulatory requirements. For patients, it means earlier access to innovative treatments that can improve quality of life and accelerate recovery.
For Inspiralia Group, this milestone reinforces our mission to transform innovation into market-ready solutions. We are proud that Adamo Robot stands as a clear example of how determination, expertise, and vision can overcome barriers and deliver tangible impact.
Gratitude and recognition
None of this would have been possible without the extraordinary commitment of our team and the trust of our collaborators. Engineers, medical advisors, regulatory specialists, project managers, and partners all played a crucial role in this achievement. Their effort, perseverance, and passion have brought us to this defining moment.
As we look to the future, we remain committed to advancing health technologies that empower professionals, improve patient outcomes, and push the boundaries of what is possible.
Today, Adamo Robot is officially CE-certified as a Class IIa Medical Device — and this is only the beginning. 🚀